Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601)

详细信息    查看全文

• 作者：John MS Bartlett ; Alison F Munro ; Janet A Dunn ; Christopher McConkey ; Sarah Jordan ; Chris J Twelves ; David A Cameron ; Jeremy Thomas ; Fiona M Campbell ; Daniel W Rea ; Elena Provenzano ; Carlos Caldas ; Pa
• 刊名：Lancet Oncology
• 出版年：2010
• 出版时间：March 2010
• 年：2010
• 卷：11
• 期：3
• 页码：266-274
• 全文大小：133 K

文摘

Summary

Background

The NEAT/BR9601 trial showed benefit for addition of anthracyclines to cyclophosphamide, methotrexate, and fluorouracil (CMF) as adjuvant treatment for early breast cancer. We investigated prospectively predictive biomarkers of anthracycline benefit including HER2 and TOP2A.

Methods

1941 tumours from 2391 women recruited to NEAT/BR9601 were analysed on tissue microarrays for HER2 and TOP2A amplification and deletion, HER1–3 and Ki67 expression, and duplication of chromosome 17 centromere enumeration probe (Ch17CEP). Log-rank analyses identified factors affecting relapse-free and overall survival, and regression models tested independent prognostic effect of markers, with adjustment for known prognostic factors (age, nodal status, oestrogen-receptor status, grade, and tumour size). The predictive value of markers was tested by treatment interactions for relapse-free and overall survival.

Findings

1762 patients were analysed. 21 % of tumours (n=367) were HER2 amplified, 10 % were TOP2A amplified (n=169), 11 % showed TOP2A deleted (n=191), 23 % showed Ch17CEP duplication (n=406), and 61 % had high (>13·0 % ) Ki67 (n=1136). In univariate analyses, only HER2 amplification and TOP2A deletion were significant prognostic factors for relapse-free (hazard ratio [HR] 1·59, 95 % CI 1·32–1·92, p<0·0001; and 1·52, 1·20–1·92, p=0·0006, respectively) and overall survival (1·79, 1·47–2·19, p<0·0001; and 1·62, 1·26–2·08, p=0·0002 respectively). We detected no significant interaction with anthracycline benefit for Ki67, HER2, HER1–3, or TOP2A. By contrast, in multivariate analyses, Ch17CEP duplication was associated with significant improvements in both relapse-free (HR 0·92, 95 % CI 0·72–1·18 for tumours with normal Ch17CEP vs 0·52, 0·34–0·81 for tumours with abnormal Ch17CEP; p for interaction=0·004) and overall survival (0·94, 0·72–1·24 vs 0·57, 0·36–0·92; p for interaction=0·02) with anthracycline use.

Interpretation

In women with early breast cancer receiving adjuvant chemotherapy, the most powerful predictor of benefit from anthracyclines is Ch17CEP duplication. In view of the location of HER2/TOP2A on chromosome 17, Ch17CEP duplication might explain the inconsistencies in previous studies of factors predicting benefit from anthracyclines.

Funding

Cancer Research UK and the Scottish Breast Cancer Clinical Trials Group.